ERBB2 and breast carcinoma: These data suggest that continued use of trasuzumab in HER2+ breast cancer patients with PTEN inactivation may pose potential challenges for second line targeted therapies due to induction of EMT, expansion of BCSC populations, and by switching the molecular subtype to triple negative.